Gene Expression Profiling for Early-stage NSCLC
Authors:
- Frunze PetrosyanFPFrunze Petrosyan
- Hamed DawHDHamed Daw
- Abdo HaddadAHAbdo Haddad
- Timothy SpiroTSTimothy Spiro
- Ruchi SoodRSRuchi Sood
- 1 February 2015
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 38 (1) , 103-107
Abstract
Lung cancer is the leading cause of cancer-related death in both developed and developing countries with unacceptably high mortality even for early-stage cancers. Present guidelines do not recommend adjuvant chemotherapy for stage I non-small cell lung carcinoma and prompts a search for a prognostic marker that would separate stage I patients into 2 groups, those who would benefit and those who would not benefit from adjuvant treatment. Studies during the last decade showed that the gene expression profiling can be the biomarker being sought. Many gene expression profiling have been found and reported from the analysis of surgical specimens of resected lung cancers during the last decade, and many of them had been shown to have an excellent predictive accuracy. These profiles used in the studies had not only different gene combinations but also different number of genes and methods of identification. Researchers have used microarray assays, RT-quantitative polymerase chain reaction, and more recently microRNA-based techniques to achieve this goal. Unfortunately, most of the profiles were not sufficiently validated and/or were not used in prospective phase III studies. This review focuses on major studies in the field, future prospects, as well as the lessons learned so far. It is shown that the gene expression profiles have a good chance of being implemented in future everyday practice.Keywords
This publication has 38 references indexed in Scilit:
- The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groupsThe Journal of Thoracic and Cardiovascular Surgery, 2012
- Lung Cancer ScreeningJournal of the National Comprehensive Cancer Network, 2012
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJournal of Clinical Oncology, 2008
- Non-Overlapping and Non–Cell-Type–Specific Gene Expression Signatures Predict Lung Cancer SurvivalJournal of Clinical Oncology, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung CancerPLOS Medicine, 2006
- RETRACTED: A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Gene Expression Signatures for Predicting Prognosis of Squamous Cell and Adenocarcinomas of the LungCancer Research, 2006
- Gene expression-based, individualized outcome prediction for surgically treated lung cancer patientsOncogene, 2004
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002